share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

Biodexa Pharmaceuticals | 6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/11/02 05:22

Moomoo AI 已提取核心訊息

Biodexa Pharmaceuticals announced the appointment of PKF Littlejohn LLP as its new independent registered public accounting firm, effective October 31, 2024, following the resignation of Forvis Mazars LLP on October 25, 2024. The change was initiated after Forvis Mazars's notice of intent to resign, followed by a tender process evaluating both commercial terms and expertise of potential candidates.The reports from Forvis Mazars for fiscal years 2022 and 2023 contained no adverse opinions, except for a modification regarding the company's ability to continue as a going concern. During these periods and through October 25, 2024, there were no disagreements on accounting principles, practices, financial statement disclosure, or auditing procedures.The company confirmed that prior to the appointment, there were no consultations with PKF Littlejohn regarding accounting principles, audit opinions, or financial reporting matters. The transition process complies with SEC reporting requirements, with Forvis Mazars providing a letter to the SEC confirming these disclosures.
Biodexa Pharmaceuticals announced the appointment of PKF Littlejohn LLP as its new independent registered public accounting firm, effective October 31, 2024, following the resignation of Forvis Mazars LLP on October 25, 2024. The change was initiated after Forvis Mazars's notice of intent to resign, followed by a tender process evaluating both commercial terms and expertise of potential candidates.The reports from Forvis Mazars for fiscal years 2022 and 2023 contained no adverse opinions, except for a modification regarding the company's ability to continue as a going concern. During these periods and through October 25, 2024, there were no disagreements on accounting principles, practices, financial statement disclosure, or auditing procedures.The company confirmed that prior to the appointment, there were no consultations with PKF Littlejohn regarding accounting principles, audit opinions, or financial reporting matters. The transition process complies with SEC reporting requirements, with Forvis Mazars providing a letter to the SEC confirming these disclosures.
Biodexa製藥公司宣佈，PKF Littlejohn LLP將於2024年10月31日起擔任其新的獨立註冊公共會計師事務所，此前Forvis Mazars LLP於2024年10月25日辭職。該變更是在Forvis Mazars宣佈辭職意向後發起的，隨後進行了評估候選人商業條款和專業能力的招標過程。Forvis Mazars對2022和2023財政年度的報告沒有發表不利意見，除了對公司持續經營能力的修正。在此期間及至2024年10月25日，雙方在會計原則、實踐、財務報表披露或審計程序上沒有分歧。該公司確認，在任命之前，未與PKF Littlejohn就會計原則、審計意見或財務報告事宜進行諮詢。過渡過程符合SEC的報告要求，Forvis Mazars已向SEC提供了一封確認這些披露的信函。
Biodexa製藥公司宣佈，PKF Littlejohn LLP將於2024年10月31日起擔任其新的獨立註冊公共會計師事務所，此前Forvis Mazars LLP於2024年10月25日辭職。該變更是在Forvis Mazars宣佈辭職意向後發起的，隨後進行了評估候選人商業條款和專業能力的招標過程。Forvis Mazars對2022和2023財政年度的報告沒有發表不利意見，除了對公司持續經營能力的修正。在此期間及至2024年10月25日，雙方在會計原則、實踐、財務報表披露或審計程序上沒有分歧。該公司確認，在任命之前，未與PKF Littlejohn就會計原則、審計意見或財務報告事宜進行諮詢。過渡過程符合SEC的報告要求，Forvis Mazars已向SEC提供了一封確認這些披露的信函。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！